VTC's first generation tests provided the key scientific basis for the development of the second generation quantitative magnetic tests. The second generation tests utilize Magnetic Immunoassay technology that turns qualitative (visual) tests into quantitative (objective) assays. The technology has a very high sensitivity (higher than ELISA laboratory tests), provides a printable record and returns results in 10 to 20 seconds
VTC's immunoassays are based on the MBS Magnetic ImmunoChromatographic Test ("MICT"), where the binding of an antigen to an antibody attached to a paramagnetic nanoparticle can be precisely measured in a quantitative form with a patented MBS magnetic reader.
The technology surrounding VACCI-TEST™ second generation products was the result of an exclusive Licensing Agreement with MagnaBioSciences LLC ("MBS") of San Diego, California, a subsidiary of Quantum Design and a world leader in magnetic measurement technology since 1982.